BI 907828 Demonstrates Early Efficacy, Safety in MDM2-amplified Dedifferentiated Liposarcoma

The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.

Related Keywords

Leuven ,Region Flamande ,Belgium ,Shanghai ,China ,Patrick Schoffski ,Acta Biochim Biophys ,University Hospitals Leuven ,Boehringer Ingelheim ,Rare Cancers Congress ,Oncology At Leuven Cancer Institute ,Rare Cancers ,General Medical Oncology ,Leuven Cancer Institute ,Sartar Therapeutics ,Ellipses Pharma ,Merck Healthcare ,Biochim Biophys Sin ,Sarcomas Tgct ,News ,2023 Esmo Sarcoma And Rare Cancers Congress ,Nct03449381 ,Dedifferentiated Liposarcoma ,